Publications

Mutant KRAS is a druggable target for pancreatic cancer

ABSTRACT: Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We propose an approach to target KRAS effectively in patients using RNA interference. To meet this challenge, we have developed

Read More »

Multistep, effective drug distribution within solid tumors

Amotz Shemi, Elina Zorde Khvalevsky, Rachel Malka Gabai, Abraham Domb, Yechezkel Barenholz, Oncotarget , Sep 22, 2015 Abstract: The distribution of drugs within solid tumors presents a long-standing barrier for efficient cancer therapies. Tumors are highly resistant to diffusion, and the lack of blood and lymphatic flows suppresses convection. Prolonged, continuous intratumoral drug delivery from a

Read More »

Preclinical Safety Evaluation in Rats of a Polymeric Matrix Containing an siRNA Drug Used as a Local and Prolonged Delivery System for Pancreatic Cancer Therapy

Ramot Y, Rotkopf S, Gabai RM, Khvalevsky EZ, Muravnik S, Marzoli GA, Domb AJ, Shemi A, Nyska A. Abstract: Conventional chemotherapy treatments for pancreatic cancer are mainly palliative. RNA interference (RNAi)-based drugs present the potential for a new targeted treatment. LOcal Drug EluteR (LODERTM) is a novel biodegradable polymeric matrix

Read More »

Better Targeting, Delivery of RNAi Therapies

Richard A. Stein. Genetic Engineering & Biotechnology News. 2017. An advantage of the LODER platform is that it delivers RNAi locally, within the tumor, Circumventing systemic toxicity and the need for large systemically administered doses. “We have preclinical and clinical data showing that our treatment is safe,” asserts Dr. Shemi.

Read More »